Predicting efficacy of sub-anesthetic ketamine/esketamine i.v. dose during course of cesarean section for PPD prevention, utilizing traditional logistic regression and machine learning models

J Affect Disord. 2023 Oct 15:339:264-270. doi: 10.1016/j.jad.2023.07.048. Epub 2023 Jul 13.

Abstract

Objective: Increasing researches supported that intravenous ketamine/esketamine during the perioperative period of cesarean section could prevent postpartum depression(PPD). With the effective rate ranging from 87.2 % to 95.5 % in PPD, ketamine/esketamine's responsiveness was individualized. To optimize ketamine dose/form based on puerpera prenatal characteristics, reducing adverse events and improving the total efficacy rate, prediction models were developed to predict ketamine/esketamine's efficacy.

Method: Based on two randomized controlled trials, 12 prenatal features of 507 women administered the ketamine/esketamine intervention were collected. Traditional logistics regression, SVM, random forest, KNN and XGBoost prediction models were established with prenatal features and dosage regimen as predictors.

Results: According to the logistic regression model (ain = 0.10, aout = 0.15, area under the receiver operating characteristic curve, AUC = 0.728), prenatal Edinburgh Postnatal Depression Scale (EPDS) score ≥ 10, thoughts of self-injury and bad mood during pregnancy were associated with poorer ketamine efficacy in PPD prevention, whilst a high dose of esketamine (0.25 mg/kg loading dose+2 mg/kg PCIA) was the most effective dosage regimen and esketamine was more recommended rather than ketamine in PPD. The AUCvalidation set of KNN and XGBoost model were 0.815 and 0.651, respectively.

Conclusion: Logistic regression and machine learning algorithm, especially the KNN model, could predict the effectiveness of ketamine/esketamine iv. during the course of cesarean section for PPD prevention. An individualized preventative strategy could be developed after entering puerpera clinical features into the model, possessing great clinical practice value in reducing PPD incidence.

Keywords: Esketamine; Ketamine; Machine learning; Postpartum depression.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anesthetics* / therapeutic use
  • Cesarean Section / adverse effects
  • Depression, Postpartum* / drug therapy
  • Depression, Postpartum* / prevention & control
  • Depressive Disorder, Treatment-Resistant* / drug therapy
  • Female
  • Humans
  • Ketamine* / therapeutic use
  • Logistic Models
  • Pregnancy

Substances

  • Esketamine
  • Ketamine
  • Anesthetics